Abstract
The use of intravitreal injections of anti-Vascular Endothelial Growth Factor (anti-VEGF) has been used for a broad spectrum of ocular pathologic entities. Although the dose of anti-VEGF agents used for treating eye disease is minute compared with that used intravenously, intraocular administration can lead to systemic absorption and reduce serum VEGF levels. Several systemic side effects, such as hypertension and cardiovascular complications have been rarely reported in the literature.
Renal complications of intravenous administration of anti-VEGF, are well known and include a variety of renal pathological damage which can induce proteinuria and hypertension.
We describe herein, 2 cases of diabetic patients with preexisting kidney disease who presented severe reduction of their renal function after intraocular administration of anti-VEGF. Although a cause –effect correlation cannot be established unless further studies are performed, we believe that pretreatment counseling should include a discussion outlining the possible risk of aggravating of the renal function in patients with kidney disease. Close cooperation with the patient’s nephrologist and close monitoring of the patient may be required, in such cases, in order to monitor the renal function before and after the intravitreal administration of anti-VEGF.
Keywords: Diabetic retinopathy, intravitreal anti-vascular endothelial growth factor, renal damage.
Current Drug Safety
Title:Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?
Volume: 9 Issue: 2
Author(s): Ilias Georgalas, Dimitris Papaconstantinou, Kostas Papadopoulos, Dionisis Pagoulatos, Dimitris Karagiannis and Chryssanthi Koutsandrea
Affiliation:
Keywords: Diabetic retinopathy, intravitreal anti-vascular endothelial growth factor, renal damage.
Abstract: The use of intravitreal injections of anti-Vascular Endothelial Growth Factor (anti-VEGF) has been used for a broad spectrum of ocular pathologic entities. Although the dose of anti-VEGF agents used for treating eye disease is minute compared with that used intravenously, intraocular administration can lead to systemic absorption and reduce serum VEGF levels. Several systemic side effects, such as hypertension and cardiovascular complications have been rarely reported in the literature.
Renal complications of intravenous administration of anti-VEGF, are well known and include a variety of renal pathological damage which can induce proteinuria and hypertension.
We describe herein, 2 cases of diabetic patients with preexisting kidney disease who presented severe reduction of their renal function after intraocular administration of anti-VEGF. Although a cause –effect correlation cannot be established unless further studies are performed, we believe that pretreatment counseling should include a discussion outlining the possible risk of aggravating of the renal function in patients with kidney disease. Close cooperation with the patient’s nephrologist and close monitoring of the patient may be required, in such cases, in order to monitor the renal function before and after the intravitreal administration of anti-VEGF.
Export Options
About this article
Cite this article as:
Georgalas Ilias, Papaconstantinou Dimitris, Papadopoulos Kostas, Pagoulatos Dionisis, Karagiannis Dimitris and Koutsandrea Chryssanthi, Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?, Current Drug Safety 2014; 9 (2) . https://dx.doi.org/10.2174/1574886309666140211113635
DOI https://dx.doi.org/10.2174/1574886309666140211113635 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cell Therapies for Intracerebral Hemorrhages
Current Drug Delivery Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science The Hellp Syndrome: A Review
Current Women`s Health Reviews Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets Directed Differentiation of Pluripotent Cells Towards Therapeutic Stem Cells
Recent Patents on Regenerative Medicine Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design Effect of Intravitreal Injection of Aflibercept on Cardiovascular Risk Parameters in Patients with Neovascular Age-Related Macular Degeneration
Current Reviews in Clinical and Experimental Pharmacology Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications
Current Medicinal Chemistry The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets The Structural Alteration and Aggregation of Bovine Lens Gamma-Crystallin by Homocysteinylation; The Pathomechanism Underlying Cataract Development During Hyperhomocysteinimia
Protein & Peptide Letters Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?
Current Drug Delivery Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research Effect of Homocysteinylation on Structure, Chaperone Activity and Fibrillation Propensity of Lens Alpha-crystallin
Protein & Peptide Letters Models for the Study of Angiogenesis
Current Pharmaceutical Design Targeting Vascular Neural Network in Intracerebral Hemorrhage
Current Pharmaceutical Design